In a landmark decision poised to reshape the standard of care, the U.S. Food and Drug Administration has approved a new maintenance regimen for patients with a specific and stubbornly aggressive form of metastatic breast cancer. The therapy adds the CDK4/6 inhibitor palbociclib to a backbone of anti-HER2 and endocrine therapy for tumors that are both hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-positive (HER2+). This approval, grounded in the international phase 3 PATINA trial, confronts a central clinical crisis: even when these “double-positive” cancers initially respond to dual-targeted treatment, they almost invariably develop resistance, allowing the disease to inexorably progress.
The PATINA study, spearheaded by Otto Metzger, MD, of Dana-Farber Cancer Institute, and conducted across six multinational research groups, delivered a stunning survival signal. Investigators reported a median progression-free survival of 44.3 months for patients receiving palbociclib combined with anti-HER2 therapy and endocrine therapy, compared to just 29.1 months for those on the standard dual therapy alone. That 15.2-month gap represents more than a year of additional life without the tumor growing or metastasizing further, a magnitude of benefit rarely observed in this heavily treated population. The findings were published in the New England Journal of Medicine and simultaneously electrified the San Antonio Breast Cancer Symposium in late 2024.
At the molecular level, the success of this triple-combination strategy hinges on the fundamental biology of the cell cycle. HR+/HER2+ breast cancers rely on a complex crosstalk between the estrogen receptor pathway and the HER2 signaling network to drive proliferation. While anti-HER2 antibodies such as trastuzumab and pertuzumab block extracellular receptor dimerization and downstream kinase cascades, and endocrine therapy starves the cancer of estrogenic fuel, the tumor cells can circumvent these blockades by hyperactivating cyclin-dependent kinases 4 and 6. These CDKs phosphorylate the retinoblastoma protein, unleashing E2F transcription factors that thrust the cell past the G1 checkpoint into DNA synthesis. Palbociclib, a potent and selective CDK4/6 inhibitor, arrests this escape route, restoring a pincer-like blockade that appears to delay the emergence of resistant clones. The PATINA data suggest that layering this cell-cycle brake onto the existing anti-HER2 and endocrine backbone disrupts the adaptive signaling that otherwise sustains minimal residual disease.
The trial enrolled patients whose metastatic disease had not progressed during initial induction therapy with taxane-based chemotherapy plus dual anti-HER2 antibodies, a design that mirrors the real-world sequence of maintenance therapy. By mandating this induction phase, the researchers ensured that the study population consisted of tumors with demonstrated sensitivity to HER2-directed therapy, yet with a high risk of eventual relapse. Participants were then randomized to receive palbociclib or placebo, each on top of continued trastuzumab with or without pertuzumab and an aromatase inhibitor. The primary endpoint of investigator-assessed progression-free survival was met with a hazard ratio of 0.74, a statistically robust reduction in the risk of disease progression or death. Toxicity was consistent with the known safety profile of palbociclib, with neutropenia being the most common grade 3 adverse event, but no new safety signals emerged.
This approval is particularly significant because the HR+/HER2+ subtype, which accounts for approximately 10 percent of all breast cancers, has long occupied a therapeutic gray zone. Clinical trials historically segregated patients by HER2 status or hormone receptor status, leaving the biology of co-positive tumors understudied. The PATINA regimen finally provides a tailored, evidence-based strategy that specifically addresses the unique signaling dependencies of these cells. The extension of progression-free survival beyond three and a half years represents a new benchmark for maintenance therapy, and it establishes CDK4/6 inhibition as a cornerstone of management for this molecular niche.
The implications extend beyond the immediate clinical impact. The PATINA results reinforce a broader paradigm shift in oncology: that the most durable responses may require simultaneous blockade of multiple, orthogonal resistance pathways rather than sequential single-agent escalation. The trial also raises provocative questions about whether the same triple-therapy approach could be applied earlier in the disease course, perhaps in the adjuvant setting for high-risk early-stage HR+/HER2+ breast cancer, or combined with newer antibody-drug conjugates that are making their own strides in HER2-low and HER2-positive disease.
For the thousands of patients living with metastatic HR+/HER2+ breast cancer, the approval of palbociclib in this setting transforms a previously inevitable decline into a far more distant horizon. It is a testament to the power of international collaborative trials and the sophisticated understanding of oncogenic signaling that now translates directly into months and years of life. As Dr. Metzger noted, the addition of palbociclib during the maintenance phase can meaningfully extend the time patients go without their disease progressing, offering oncologists a long-awaited, evidence-based tool to optimize long-term control.
Subject of Research: Efficacy and safety of palbociclib added to anti-HER2 therapy and endocrine therapy in patients with HR+, HER2+ metastatic breast cancer.
Article Title: Palbociclib plus Anti-HER2 Therapy and Endocrine Therapy in Hormone Receptor–Positive, HER2-Positive Metastatic Breast Cancer
News Publication Date: April 2025
Web References: https://www.nejm.org/doi/full/10.1056/NEJMoa2511218, https://www.dana-farber.org/find-a-doctor/otto-metzger
References: Metzger O, et al. N Engl J Med. 2025; DOI: 10.1056/NEJMoa2511218.
Image Credits:
Keywords: Breast cancer, palbociclib, CDK4/6 inhibitor, HER2-positive, hormone receptor-positive, metastatic, PATINA, progression-free survival, FDA approval, cell cycle, resistance.
